

Certificate of Analysis for MRA-155

Plasmodium falciparum, Strain HB3

Catalog No. MRA-155

This reagent is the tangible property of the U.S. Government.

Product Description: Plasmodium falciparum (P. falciparum), strain HB3 was cloned from the Honduras I/CDC strain, originally isolated from a patient in Choluteca, Honduras, during an outbreak of urban malaria in January 1980.

Lot¹: 70014464 Manufacturing Date: 17APR2018

TEST	SPECIFICATIONS	RESULTS	
Identification by Giemsa Stain Microscopy ^{2,3}	Blood-stage parasites present	Blood-stage parasites present	
Antimalarial Susceptibility Profile (in vitro) ² Half-maximal Inhibitory Concentration (IC50) by SYBR green I [®] drug sensitivity assay ⁴			
Chloroquine Artemisinin Quinine Cycloguanil Pyrimethamine Sulfadoxine	Report results	7.8 ± 0.4 nM 14.8 ± 0.3 nM 41.6 ± 1.0 nM 32.8 ± 0.8 nM 2346 ± 54.0 nM 579100 ± 107279 nM	
Genotypic Analysis ² Sequencing of Merozoite Surface Protein 2 (MSP2) gene (~ 720 base pairs)	≥ 99% sequence identity to P. falciparum, strain HB3 (GenBank: AANS01000284)	99.9% sequence identity to P. falciparum, strain HB3 (GenBank: AANS01000284) (Figure 1)	
Functional Activity by PCR Amplification ² MSP2 PCR amplicon analysis ⁵	~ 600 to 900 base pair amplicon	~ 800 base pair amplicon	
Level of Parasitemia Pre-freeze ^{6,7}			
Ring-stage parasitemia Total parasitemia Post-freeze ^{2,8}	Report results ≥ 2%	5.57% 6.89%	
Ring-stage parasitemia Total parasitemia	Report results ≥ 1%	0.90% 1.25%	
Viability (post-freeze) ^{2,9}	Growth in infected red blood cells	Growth in infected red blood cells	
Sterility (21-day incubation) ² Harpo's HTYE broth ¹⁰ , 37°C and 26°C, aerobic Tryptic Soy broth, 37°C and 26°C, aerobic Sabouraud Dextrose broth, 37°C and 26°C, aerobic DMEM with 10% FBS, 37°C, aerobic Sheep Blood agar, 37°C, aerobic Sheep Blood agar, 37°C, anaerobic Thioglycollate broth, 37°C, anaerobic	No growth	No growth	
Mycoplasma Contamination ² DNA Detection by PCR	None detected	None detected	

MRA-155 was produced by cultivation of BEI Resources MR-MRA-155 lot 58243283 in fresh human erythrocytes suspended in RPMI 1640 medium, adjusted to contain 10% (v/v) heat-inactivated human serum (pooled Type A), 25 mM HEPES, 2 mM L-glutamine, 4 g/L D-glucose, 0.005 μg/mL hypoxanthine and 2.5 μg/mL gentamicin. The culture was incubated at 37°C in sealed flasks outgassed with blood-gas atmosphere (90% N₂, 5% CO₂, 5% O₂) and monitored for parasitemia daily for 11 days. Every 1 to 3 days, uninfected, leukocyte filtered, Type O erythrocytes in complete culture medium were added dropwise to the culture as needed and monitored for hematocrit.

BEI Resources

www.beiresources.org

E-mail: contact@beiresources.org

Tel: 800-359-7370 Fax: 703-365-2898



Certificate of Analysis for MRA-155

Figure 1: MRA-155 MSP2 Sequence

ATTTTTGTTA	CCTTTAATAT	TAAAAATGAA	AGTAAATATA	GCAACACATT	CATAAACAAT	GCTTATAATA	TGAGTATAAG
GAGAAGTATG	GCAAATGAAG	GTTCTAATAC	TAAGAGTGTA	GGTGCAAATG	CTCCAAAAGC	TGATACTATT	GCTAGTGGAA
GTCAAAGTAG	TACAAATAGT	GCAAGTACTA	GTACTACTAA	TAATGGAGAA	TCACAAAATA	CTACTCCTAC	CGCTGCTGAT
ACCCCTACTG	CTACAGAAAG	TAATTCACCT	TCACCACCCA	TCACTACTAC	AGAAAGTAAT	TCACCTTCAC	CACCCATCAC
TACTACAAAA	AGTAATTCAC	CTTCACCACC	CATCACTACT	ACAGAAAGTT	CAAGTTCTGG	CAATGCACCA	AATAAAACAG
ACGGTAAAGG	AGAAGAGAGT	GAAAAACAAA	ATGAATTAAA	TGAATCAACT	GAAGAAGGAC	CCAAAGCTCC	ACAAGAACCT
CAAACGGCAG	AAAATGAAAA	TCCTGCTGCA	CCAGAGAATA	AAGGTACAGG	ACAACATGGA	CATATGCATG	GTTCTAGAAA
TAATCATCCA	CAAAATACTT	CTGATAGTCA	AAAAGAATGT	ACCGATGGTA	ACAAAGAAAA	CTGTGGAGCA	GCAACATCCC
TCTTAAATAA	CTCTAGTAAT	ATTGCTTCAA	TAAATAAATT	TGTTGTTTTA	ATTTCARCAA	CACTTGTTTT	ATCTTTT

/Heather Couch/

Heather Couch 05 JUL 2018

Program Manager or designee, ATCC Federal Solutions

ATCC®, on behalf of BEI Resources, hereby represents and warrants that the material provided under this certificate has been subjected to the tests and procedures specified and that the results described, along with any other data provided in this certificate, are true and accurate to the best of ATCC®'s knowledge.

ATCC® is a trademark of the American Type Culture Collection.

You are authorized to use this product for research use only. It is not intended for human use.

Support Provided by NIAID

BEI Resources
www.beiresources.org

E-mail: contact@beiresources.org

Tel: 800-359-7370 Fax: 703-365-2898

MRA-155 70014464 05JUL2018

²Testing completed on vialed post-freeze material.

³Blood-stage malaria parasites (rings, trophozoites, schizonts +/- gametocytes) were examined by microscopic Giemsa-stained blood smears of an *in vitro* human blood culture over 5 days.

⁴A SYBR Green I[®] anti-malarial drug sensitivity assay in 96-well plates was used to determine IC₅₀ values of an active (> 70% ring stage) parasite culture in the presence of each antimalarial drug [Hartwig, C. L., et al. "XI: I. SYBR Green I[®]-Based Parasite Growth Inhibition Assay for Measurement of Antimalarial Drug Susceptibility in *Plasmodium falciparum*." In Methods in Malaria Research Sixth Edition. (2013) Moll, K., et al. (Ed.), EVIMalaR, pp. 122-129. Available at: https://www.beiresources.org/Publications/MethodsinMalariaResearch.aspx].

⁵Primer sequences and conditions for PCR are available upon request.

⁶Testing completed on bulk material prior to vialing and freezing.

⁷Parasitemia was determined after 11 days post infection by microscopic counts of Giemsa-stained blood smears.

⁸Post-freeze parasitemia was determined after 5 days post infection by microscopic counts of Giemsa-stained blood smears.

⁹Viability was confirmed by examination of infected erythrocytes for parasitemia at 5 days post infection.

¹⁰Atlas, Ronald M. <u>Handbook of Microbiological Media</u>. 3rd ed. Ed. Lawrence C. Parks. Boca Raton: CRC Press, 2004, p. 798.